Regent Peak Wealth Advisors LLC Has $2.78 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Regent Peak Wealth Advisors LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 1.8% during the fourth quarter, Holdings Channel reports. The fund owned 9,639 shares of the medical research company’s stock after selling 178 shares during the quarter. Regent Peak Wealth Advisors LLC’s holdings in Amgen were worth $2,776,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. OFI Invest Asset Management bought a new position in shares of Amgen in the third quarter worth approximately $26,000. Briaud Financial Planning Inc bought a new position in Amgen during the third quarter valued at approximately $26,000. VisionPoint Advisory Group LLC bought a new position in shares of Amgen in the second quarter worth approximately $28,000. Strategic Investment Solutions Inc. IL bought a new position in shares of Amgen in the first quarter worth approximately $28,000. Finally, Providence Capital Advisors LLC purchased a new stake in Amgen in the third quarter worth $30,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on AMGN shares. BMO Capital Markets raised Amgen from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $286.00 to $326.00 in a research report on Tuesday, December 19th. Leerink Partnrs cut Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Oppenheimer reaffirmed an “outperform” rating and set a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $264.00 to $320.00 in a report on Thursday, December 21st. Finally, Raymond James assumed coverage on Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $295.30.

Read Our Latest Report on Amgen

Amgen Trading Down 2.4 %

NASDAQ AMGN traded down $6.83 on Tuesday, reaching $276.21. The stock had a trading volume of 2,220,460 shares, compared to its average volume of 3,009,285. The firm has a market capitalization of $148.03 billion, a price-to-earnings ratio of 22.38, a P/E/G ratio of 2.69 and a beta of 0.58. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The stock has a fifty day moving average price of $288.67 and a two-hundred day moving average price of $281.34.

Amgen (NASDAQ:AMGNGet Free Report) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.09 earnings per share. As a group, sell-side analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.26%. Amgen’s dividend payout ratio (DPR) is 72.06%.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.